title: Impact of intensive statin use on the level of inflammation and platelet activation in stable angina after percutaneous coronary intervention: a clinical study.
abstract: OBJECTIVE
  This study was designed to investigate whether high-dose atorvastatin before percutaneous coronary intervention (PCI) can reduce inflammation, platelet activation, and major adverse cardiac events (MACE) in patients with stable angina who are undergoing long-term statin therapy.
  
  
  METHODS
  In total, 215 patients with chronic stable angina were randomized to pretreatment with 80 mg of atorvastatin (12 h before PCI; n = 106) or with 20 mg of atorvastatin (12 h before PCI; n = 109). All patients underwent PCI. Serum levels of interleukin-6, high-sensitivity C-reactive protein, tumor necrosis factor-α, GMP-140, and p-selectin were measured 24 h before and after PCI. The 30-day incidence of MACE was determined.
  
  
  RESULTS
  No differences in baseline characteristics were observed between the groups. The levels of inflammation and platelet activation were significantly lower after 24 h in the group that received intensive statin therapy (P < 0.05). The levels of inflammation and platelet activation increased sharply 24 h after PCI in the group that received the lower dose of atorvastatin (P > 0.05). In other words, pretreatment with a high dose of atorvastatin decreased the incidence of MACE sharply within 30 days (P < 0.05).
  
  
  CONCLUSIONS
  Pretreatment with a high dose of atorvastatin significantly reduced inflammation, platelet activation, and the incidence of MACE in patients with stable angina.
authors.affiliation: Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, PR China.
authors.forename: Qing
authors.initials: Q
authors.lastname: Li
authors.forename: Song-Bai
authors.initials: SB
authors.lastname: Deng
authors.forename: Shuang
authors.initials: S
authors.lastname: Xia
authors.forename: Jian-Lin
authors.initials: JL
authors.lastname: Du
authors.forename: Qiang
authors.initials: Q
authors.lastname: She
mesh_terms: D000368:Aged; D000787:Angina Pectoris / Q000097:blood / Q000188:drug therapy / Q000628:therapy*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use; D000069059:Atorvastatin; D004730:Endothelium, Vascular / Q000187:drug effects; D005260:Female; D006538:Heptanoic Acids / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D007249:Inflammation / Q000097:blood / Q000188:drug therapy*; D018836:Inflammation Mediators / Q000097:blood; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention; D015539:Platelet Activation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011292:Premedication; D011446:Prospective Studies; D011758:Pyrroles / Q000494:pharmacology / Q000627:therapeutic use*; D012086:Reoperation; D016037:Single-Blind Method; D015607:Stents
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D018836:Inflammation Mediators; D010975:Platelet Aggregation Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin